This database contains 4 studies, archived under the term: "receptors dopamine d2"
Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine
Brusa, Livia,
Orlacchio, Antonio,
Moschella, Vincenzo,
Iani, Cesare,
Bernardi, Giorgio,
Mercuri, Nicola Biagio
Aripiprazole (AP), a dopamine (DA) D(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington’s disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare […]
Fetal striatal grafting slows motor and cognitive decline of Huntington’s disease
Paganini, M.,
Biggeri, A.,
Romoli, A. M.,
Mechi, C.,
Ghelli, E.,
Berti, V.,
Pradella, S.,
Bucciantini, S.,
Catelan, D.,
Saccardi, R.,
Lombardini, L.,
Mascalchi, M.,
Massacesi, L.,
Porfirio, B.,
Di Lorenzo, N.,
Vannelli, G. B.,
Gallina, P.
Objective: To assess the clinical effect of caudate-putaminal transplantation of fetal striatal tissue in Huntington’s disease (HD).; Methods: We carried out a follow-up study on 10 HD transplanted patients and 16 HD not-transplanted patients. All patients were evaluated with the Unified HD Rating Scale (UHDRS) whose change in motor, cognitive, behavioural and functional capacity total […]
Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients
Martorana, Alessandro,
Di Lorenzo, Francesco,
Esposito, Zaira,
Lo Giudice, Temistocle,
Bernardi, Giorgio,
Caltagirone, Carlo,
Koch, Giacomo
Dopamine is a neurotransmitter involved in several brain functions ranging from emotions control, movement organization to memory formation. It is also involved in the regulation of mechanisms of synaptic plasticity. However, its role in Alzheimer’s disease (AD) pathogenesis is still puzzling. Several recent line of research instead indicates a clear role for dopamine in both […]
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease
Lundin, Anders,
Dietrichs, Espen,
Haghighi, Sara,
Göller, Marie-Louise,
Heiberg, Arvid,
Loutfi, Ghada,
Widner, Håkan,
Wiktorin, Klas,
Wiklund, Leif,
Svenningsson, Anders,
Sonesson, Clas,
Waters, Nicholas,
Waters, Susanna,
Tedroff, Joakim
Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, […]